CC
NAMSW icon

Caxton Corporation’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

Caxton Corporation’s Portfolio NAMSW Stock Details NAMSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,333
Closed -$40.5K – 11
2023
Q1 		$40.5K Hold
21,333
– – 0.1% 13
2022
Q4 		$17.8K Buy
+21,333
New +$17.6K 0.05% 15

Other funds holding NAMSW

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Caxton Corporation's NAMSW Position: Q2 2023 in Review

Caxton Corporation sold out of NewAmsterdam Pharma Warrant (NAMSW) in Q2 2023, closing a stake of 21,333 shares — an estimated $40.5K sold.

Caxton Corporation first reported a position in NAMSW in Q4 2022 and held it in 2 quarters. The position peaked at $40.5K in Q1 2023. 18 funds tracked by Wall St. Rank hold NAMSW as of Q2 2023.

  • Caxton Corporation reported no remaining NewAmsterdam Pharma Warrant position as of Q2 2023 after selling out during the quarter.
  • Caxton Corporation sold 21,333 NewAmsterdam Pharma Warrant shares in Q2 2023, an estimated $40.5K.
  • Caxton Corporation first reported a position in NewAmsterdam Pharma Warrant in Q4 2022 and held it in 2 quarters.
  • Caxton Corporation's NewAmsterdam Pharma Warrant position peaked at $40.5K in Q1 2023.
  • 18 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q2 2023.

Based on Caxton Corporation's 13F filing for Q2 2023, filed 14 Aug 2023.